Pyxis Oncology, an immuno-oncology company focused on developing a new family of antibody-based immunotherapies derived from novel insights into the biology of the tumor microenvironment, today announced the appointment of Ronald Herbst, PhD, as Chief Scientific Officer effective October 15, 2019. Dr. Herbst joins Pyxis from MedImmune, where he was Vice President of Research and Development and Head of Oncology Research.

https://www.pyxisoncology.com/ronald-herbst-joins-pyxis-oncology